GlassScriptPhysician profile
Eric J Lawatsch
NPI 1033296520
$6,769.87
in general payments reported to CMS, 2019-2025
31 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $78.25 · 2021: $70.83 · 2022: $368 · 2023: $3,541 · 2024: $712 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,950 · Travel and Lodging: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,949.53 |
| Travel and Lodging | $910.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,147.22 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Procept Biorobotics Corporation | $1,177.50 | 2025 | |
| Janssen Biotech, INC. | $403.79 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $384.17 | 2019-2025 | Provenge |
| Pfizer INC. | $225.08 | 2019-2025 | |
| Urogen Pharma, INC. | $206.34 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $197.25 | 2023-2024 | Orgovyx, Gemtesa |
| Abbvie INC. | $130.33 | 2019-2025 | |
| Myovant Sciences INC. | $91.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $79.34 | 2023-2025 | Lynparza, Keytruda |
| Astellas Pharma US INC | $68.30 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $62.53 | 2019-2024 | |
| Coloplast Corp | $55.98 | 2019-2023 | Speedicath |
| Boston Scientific Corporation | $55.70 | 2019-2025 | Polaris Ultra |
| Sun Pharmaceutical Industries INC. | $46.19 | 2023-2024 | Yonsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $42.23 | 2019-2024 | Adstiladrin |
| Amgen INC. | $35.92 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $35.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.38 | 2023-2024 | |
| Teleflex LLC | $34.43 | 2022-2023 | Urolift |
| Olympus America INC. | $33.34 | 2025 | Itind System |
| Blue Earth Diagnostics | $31.89 | 2019 | |
| Allergan, INC. | $25.03 | 2019 | |
| Neotract INC. | $24.77 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $24.42 | 2022 | |
| Tempus Ai, INC | $24.29 | 2024 | |
| Palette Life Sciences, INC. | $24.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.68 | 2022 | |
| Smith+Nephew, INC. | $16.81 | 2022 | |
| Medtronic USA, INC. | $16.39 | 2019 | |
| Axonics, INC. | $15.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lawatsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.